Table 1 Demographic and clinical data based on financial status
Variables | Overall (n = 123) | Financial status |  | ||
|---|---|---|---|---|---|
Low (n = 20) | Fair (n = 47) | Good (n = 56) | P | ||
Age | 53.4 ± 9.3 | 51.5 ± 10.1 | 53.7 ± 9.8 | 53.9 ± 8.6 | 0.585 |
BMI | 21.1 ± 1.3 | 21.0 ± 1.5 | 21.2 ± 1.4 | 21.0 ± 1.1 | 0.737 |
Marital status | |||||
  Married | 113 (91.9%) | 17 (85.0%) | 42 (89.4%) | 54 (96.4%) | 0.438 |
  Singlea | 10 (8.1%) | 3 (15%) | 5 (10.6%) | 2 (3.6%) |  |
Education | |||||
 Junior high school or lower | 86 (78.0%) | 19 (95.0%) | 39 (83.0%) | 38 (67.9%) | 0.025 |
 Senior high school or above | 27 (22.0%) | 1 (5.0%) | 8 (17.0%) | 18 (32.1%) |  |
Occupation | |||||
 Farmer or housewife | 46 (37.4%) | 17 (85.0%) | 22 (46.8%) | 7 (12.5%) | <0.0001 |
 Factory worker | 15 (12.2%) | 3 (15.0%) | 6 (12.8%) | 6 (10.7%) |  |
 Enterprise employee | 20 (16.3%) |  | 3 (6.4%) | 17 (30.4%) | |
 Self-employed | 7 (5.7%) |  | 2 (4.2%) | 5 (8.9%) | |
 Retired | 35 (28.5%) |  | 14 (29.8%) | 21 (37.5%) | |
Insurance type | |||||
 Urban medical insurance | 75 (61.0%) | 3 (15.0%) | 19 (40.4%) | 53 (94.6%) | <0.0001 |
 Rural medical insurance | 48 (39.0%) | 17 (85.0%) | 28 (59.6%) | 3 (5.4%) |  |
Surgery | 23 (18.7%) | 4 (20.0%) | 9 (19.1%) | 10 (17.9%) | 0.972 |
Number of recurrences | |||||
 1 | 80 (65.0%) | 15 (75.0%) | 31 (66.0%) | 34 (60.7%) | 0.509 |
 2–10 | 43 (35.0%) | 5 (25.0%) | 16 (34.0%) | 22 (39.3%) |  |
Recurrence interval | |||||
  ≤ 12 months | 74 (60.2%) | 12 (60.0%) | 27 (57.4%) | 35 (62.5%) | 0.451 |
 12–90 months | 49 (39.8%) | 8 (40.0%) | 20 (42.6%) | 21 (37.5%) |  |
Site of recurrence | |||||
 Pelvic | 27 (22.0%) | 6 (30.0%) | 9 (19.1%) | 12 (21.4%) | 0.380 |
 Abdominal | 41 (33.3%) | 3 (15.0%) | 19 (40.4%) | 19 (33.9%) |  |
 Distant metastasis | 55 (44.7) | 11 (55.0%) | 19 (40.4%) | 25 (44.7%) | |
Chemotherapy | |||||
 Paclitaxel plus Carboplatin | 36 (29.3%) | 6 (30.0%) | 14 (29.8%) | 16 (28.6%) | 0.969 |
 Docetaxel plus Carboplatin | 34 (27.6%) | 5 (25.0%) | 11 (23.4%) | 18 (32.1%) |  |
 Gemcitabine plus Cisplatin | 33 (26.8%) | 5 (25.0%) | 14 (29.8%) | 14 (25.0%) | |
 Othersb | 20 (16.3%) | 4 (20.0%) | 8 (17.0%) | 8 (14.3%) | |